An Ultra-High Throughput Approach to High Content Screening in 1536-Well Format
Poster Feb 01, 2007
Yan Wang, Robert L. Davis and Wayne Bowen
Ultra-high throughput screening (uHTS) using Kalypsys’ technology has enabled unprecedented levels of efficiency and economy in primary screening, and has proved especially useful at rapidly profiling screening hits in selectivity and safety assays.
Combining throughput of over 1 million assay wells per day with on-line storage capacity of over 2 million compounds, the Kalypsys® Integrated Screening System provides unmatched screening efficiency.
To effectively utilize whole cell assay formats in primary and secondary screening, image-based high content readers will be required to have multi-channel capability, rapid read times and compatibility with high-density plate formats.
Laser-scanning fluorescence microplate cytometers, such as the Acumen Explorer, offer whole-well, high content analysis of 1,536- well microplates in less than 10 minutes per plate, while collecting data for up to four colours in multiplex protocols.
The Acumen Explorer thus combines the object-recognition capabilities of image-based systems with read speeds similar to that of bulk readers. Here, we demonstrate the powerful integration of an Acumen Explorer with the Kalypsys® Integrated Screening System, with capability to screen > 300,000 wells per day of high content data.
Assessment of Oral LISPRO Treatment in Ameliorating Amyloid and Tau Pathology in Transgenic Alzheimer’s Mice ModelPoster
Ionic co-crystals of lithium salicylate with organic proline (LISPRO) showed better safety and pharmacokinetic profile of lithium in plasma and brain of wild-type and transgenic Alzheimer mice model compared to lithium salts.READ MORE
CiPA Phase 2 Study: validation of an automated microelectrode array (MEA) assay of hiPSC-derived cardiomyocyte electrophysiology for cardiac safety evaluationPoster
These results support the use of hSC-CM and MEA technology for preclinical assessment of proarrhythmic risk within the proposed CiPA paradigm, and, more generally, demonstrate that automation of the CM-MEA assay can achieve high reliability and throughput for cardiac risk assessment in vitro.READ MORE
Comments | 0 ADD COMMENT
International Conference and Exhibition on Nanomedicine and Nanotechnology
Nov 23 - Nov 24, 2017
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018